Hims & Hers Health (NYSE:HIMS) CFO Sells $261,831.32 in Stock

Hims & Hers Health, Inc. (NYSE:HIMS) CFO Oluyemi Okupe sold 9,388 shares of the company’s stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $27.89, for a total value of $261,831.32. Following the transaction, the chief financial officer directly owned 264,117 shares of the company’s stock, valued at $7,366,223.13. The trade was a 3.43% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Oluyemi Okupe also recently made the following trade(s):

• On Wednesday, August 19th, Oluyemi Okupe sold 4,938 shares of Hims & Hers Health stock. The stock was sold at an average price of $29.99, for a total value of $148,090.62.
• On Thursday, June 18th, Oluyemi Okupe sold 55,383 shares of Hims & Hers Health stock. The shares were sold at an average price of $35.09, for a total value of $1,943,389.47.
• On Monday, July 6th, Oluyemi Okupe sold 7,163 shares of Hims & Hers Health stock. The shares were sold at an average price of $36.49, for a total value of $261,377.87.
• On Monday, June 22nd, Oluyemi Okupe sold 18,197 shares of Hims & Hers Health stock. The stock was sold at an average price of $34.03, for a total value of $619,243.91.

Hims & Hers Health Stock Performance

NYSE:HIMS opened at $31.95 on Friday. The stock has a market cap of $7.45 billion, a P/E ratio of -50.71 and a beta of 2.40. The firm’s fifty day simple moving average is $32.23 and its 200 day simple moving average is $26.09. Hims & Hers Health, Inc. has a twelve month low of $13.74 and a twelve month high of $65.30. The company has a quick ratio of 0.87, a current ratio of 0.93 and a debt-to-equity ratio of 4.21.

Hims & Hers Health (NYSE:HIMS) last issued its quarterly earnings data on Monday, August 10th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.32). Hims & Hers Health had a negative net margin of 5.51% and a negative return on equity of 6.51%. The company had revenue of $753.21 million for the quarter, compared to analysts’ expectations of $698.90 million. During the same period in the previous year, the firm posted $0.17 earnings per share. The firm’s revenue for the quarter was up 38.2% compared to the same quarter last year. As a group, research analysts predict that Hims & Hers Health, Inc. will post -0.05 EPS for the current year.

Analyst Ratings Changes

HIMS has been the topic of several research reports. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Hims & Hers Health in a research report on Friday, August 7th. Canaccord Genuity Group increased their target price on Hims & Hers Health from $32.00 to $40.00 and gave the stock a “buy” rating in a research report on Wednesday, July 1st. UBS Group set a $23.00 target price on Hims & Hers Health in a research note on Friday, May 22nd. Barclays lifted their price target on Hims & Hers Health from $29.00 to $39.00 and gave the company an “overweight” rating in a research report on Wednesday, June 17th. Finally, Deutsche Bank Aktiengesellschaft upped their price target on Hims & Hers Health from $25.00 to $26.00 and gave the stock a “hold” rating in a research note on Tuesday, August 11th. Four investment analysts have rated the stock with a Buy rating, eleven have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Hims & Hers Health has an average rating of “Hold” and a consensus target price of $32.43.

Key Stories Impacting Hims & Hers Health

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: CEO Andrew Dudum defended Hims & Hers against the FTC’s allegations and said the company’s strategy could improve patient access and affordability. He also discussed a potential AI health coach that could support medication adherence, creating a possible long-term technology catalyst. Hims & Hers rejects privacy allegations
• Positive Sentiment: Some investors continue to view the recent margin weakness as an opportunity, citing Hims & Hers’ 38.2% year-over-year revenue growth and potential expansion into testosterone, peptides, branded GLP-1 treatments and international markets. However, execution and profitability remain important hurdles. Hims & Hers: Buying the Margin Dip
• Neutral Sentiment: Recent insider filings show sales by CFO Oluyemi Okupe, Deborah M. Autor and Soleil Boughton. The transactions were conducted under pre-arranged Rule 10b5-1 plans, and several sales were intended to cover tax obligations from vested equity awards. Because insiders retained substantial positions, the filings are a limited bearish signal rather than clear evidence of weakening confidence. SEC insider transaction filing
• Neutral Sentiment: Analyst sentiment remains mixed. The consensus rating is “Hold,” while Needham raised its price target to $42 and maintained a Buy rating. The split view reflects strong sales growth but concerns about losses, margins and the GLP-1 business strategy.
• Negative Sentiment: The FTC litigation and new investigations by Kaplan Fox and Berger Montague add potential legal costs, compliance requirements and reputational risk. The investigations focus on alleged sharing of private health data, deceptive billing and difficult subscription cancellations, keeping regulatory uncertainty over the stock. Kaplan Fox investigation
• Negative Sentiment: Hims & Hers’ latest quarter showed a larger-than-expected loss of $0.37 per share versus the $0.05 consensus estimate, despite revenue exceeding expectations. The earnings miss and negative profitability metrics could limit the stock’s upside until margins improve.

Hedge Funds Weigh In On Hims & Hers Health

Hedge funds have recently bought and sold shares of the company. Versant Capital Management Inc increased its stake in Hims & Hers Health by 801.2% during the 2nd quarter. Versant Capital Management Inc now owns 748 shares of the company’s stock valued at $26,000 after purchasing an additional 665 shares in the last quarter. MassMutual Private Wealth & Trust FSB lifted its stake in shares of Hims & Hers Health by 70.0% in the second quarter. MassMutual Private Wealth & Trust FSB now owns 775 shares of the company’s stock worth $27,000 after buying an additional 319 shares in the last quarter. Binnacle Investments Inc bought a new position in shares of Hims & Hers Health in the third quarter worth approximately $28,000. Bogart Wealth LLC grew its holdings in shares of Hims & Hers Health by 235.8% during the fourth quarter. Bogart Wealth LLC now owns 900 shares of the company’s stock valued at $29,000 after buying an additional 632 shares during the last quarter. Finally, Geneos Wealth Management Inc. purchased a new stake in shares of Hims & Hers Health during the first quarter valued at approximately $30,000. Institutional investors own 63.52% of the company’s stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.